Latest Commercialisation News

Wide Open Agriculture Limited has trimmed its annual loss to $7.09 million while expanding its lupin protein sales pipeline across key international markets and optimizing production in Germany.

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

1414 Degrees Ltd reported a widened net loss of $3.34 million for FY25 while advancing its thermal energy storage and hydrogen reactor technologies, supported by fresh equity and government grants.

Environmental Clean Technologies Limited reported a $3.52 million net loss for FY2025, marking a modest 5% improvement, while making significant progress in commercialising its COLDry fertiliser technology and securing over $1.7 million in new capital.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.